102 related articles for article (PubMed ID: 19956854)
1. Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells.
Zhang K; Zhou YQ; Yao HP; Wang MH
Int J Oncol; 2010 Jan; 36(1):255-64. PubMed ID: 19956854
[TBL] [Abstract][Full Text] [Related]
2. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells.
Wang MH; Kurtz AL; Chen Y
Carcinogenesis; 2000 Aug; 21(8):1507-12. PubMed ID: 10910951
[TBL] [Abstract][Full Text] [Related]
4. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines.
Chen YQ; Zhou YQ; Angeloni D; Kurtz AL; Qiang XZ; Wang MH
Exp Cell Res; 2000 Nov; 261(1):229-38. PubMed ID: 11082293
[TBL] [Abstract][Full Text] [Related]
5. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.
Collesi C; Santoro MM; Gaudino G; Comoglio PM
Mol Cell Biol; 1996 Oct; 16(10):5518-26. PubMed ID: 8816464
[TBL] [Abstract][Full Text] [Related]
6. Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility.
Zhang K; Yao HP; Wang MH
Carcinogenesis; 2008 Mar; 29(3):552-9. PubMed ID: 18204077
[TBL] [Abstract][Full Text] [Related]
7. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
Wang MH; Lao WF; Wang D; Luo YL; Yao HP
Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
[TBL] [Abstract][Full Text] [Related]
8. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.
Wang MH; Yao HP; Zhou YQ
Acta Pharmacol Sin; 2006 Jun; 27(6):641-50. PubMed ID: 16723080
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.
Zhou YQ; He C; Chen YQ; Wang D; Wang MH
Oncogene; 2003 Jan; 22(2):186-97. PubMed ID: 12527888
[TBL] [Abstract][Full Text] [Related]
10. A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.
Wang D; Lao WF; Kuang YY; Geng SM; Mo LJ; He C
Exp Cell Res; 2012 Dec; 318(20):2548-58. PubMed ID: 22975341
[TBL] [Abstract][Full Text] [Related]
11. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
Chakedis J; French R; Babicky M; Jaquish D; Howard H; Mose E; Lam R; Holman P; Miyamoto J; Walterscheid Z; Lowy AM
Oncogene; 2016 Jun; 35(25):3249-59. PubMed ID: 26477314
[TBL] [Abstract][Full Text] [Related]
12. The HNRNPA2B1-MST1R-Akt axis contributes to epithelial-to-mesenchymal transition in head and neck cancer.
Gupta A; Yadav S; Pt A; Mishra J; Samaiya A; Panday RK; Shukla S
Lab Invest; 2020 Dec; 100(12):1589-1601. PubMed ID: 32669614
[TBL] [Abstract][Full Text] [Related]
13. Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity.
Wei X; Hao L; Ni S; Liu Q; Xu J; Correll PH
J Biol Chem; 2005 Dec; 280(48):40241-51. PubMed ID: 16166096
[TBL] [Abstract][Full Text] [Related]
14. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression.
Bardella C; Costa B; Maggiora P; Patane' S; Olivero M; Ranzani GN; De Bortoli M; Comoglio PM; Di Renzo MF
Cancer Res; 2004 Aug; 64(15):5154-61. PubMed ID: 15289319
[TBL] [Abstract][Full Text] [Related]
15. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
Lu Y; Yao HP; Wang MH
Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.
Wang MH; Wang D; Chen YQ
Carcinogenesis; 2003 Aug; 24(8):1291-300. PubMed ID: 12807733
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of RON-mediated epithelial-mesenchymal transition in MDCK cells through the MAPK pathway.
Xiangming X; Yun Q; Guoliang Z; Jianjiang L; Lisong T
Braz J Med Biol Res; 2011 Jul; 44(7):634-41. PubMed ID: 21655705
[TBL] [Abstract][Full Text] [Related]
18. Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence.
Côté M; Miller AD; Liu SL
Biochem Biophys Res Commun; 2007 Aug; 360(1):219-25. PubMed ID: 17588532
[TBL] [Abstract][Full Text] [Related]
19. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
